【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 988次   下载 730 本文二维码信息
码上扫一扫!
超声引导下腹横肌平面阻滞复合瑞芬太尼靶控输注在胰管结石体外震波碎石术中的应用
王春1△,陆军1△,李博1,陈辉2,薄禄龙1,卞金俊1*
0
(1. 海军军医大学(第二军医大学)长海医院麻醉学部, 上海 200433;
2. 海军军医大学(第二军医大学)长海医院消化内科, 上海 200433
共同第一作者
*通信作者)
摘要:
目的 评价超声引导下腹横肌平面阻滞复合瑞芬太尼靶控输注应用于胰管结石体外震波碎石术(ESWL)中的效果。方法 选择60例首次接受ESWL治疗的胰管结石患者,随机分为R组和TR组,每组30例。R组患者仅接受瑞芬太尼靶控输注,TR组患者接受瑞芬太尼靶控输注前30 min行超声引导下腹横肌平面阻滞。采用Dixon序贯法计算两组患者的瑞芬太尼半数效应浓度(EC50),记录患者围手术期疼痛视觉模拟量表(VAS)评分、Ramsay镇静评分、血流动力学参数、呼吸参数和不良反应。结果 R组和TR组患者瑞芬太尼EC50分别为3.448ng/mL(95%CI 1.636~3.946 ng/mL)和2.523 ng/mL(95%CI 0.744~2.991 ng/mL),差异有统计学意义(P<0.05)。两组患者的VAS评分和Ramsay镇静评分相当(P均>0.05),血流动力学参数和呼吸参数差异均无统计学意义(P均>0.05)。TR组患者瘙痒发生率[6.7%(2/30)vs 26.7%(8/30),P=0.038]和总不良反应发生率[10.0%(3/30)vs 56.7%(17/30),P<0.001]低于R组。结论 腹横肌平面阻滞复合瑞芬太尼靶控输注可为胰管结石ESWL提供满意的镇痛和镇静效果,减少术中瑞芬太尼用量,降低不良反应的发生率。
关键词:  超声引导  腹横肌平面阻滞  靶控输注  瑞芬太尼  体外震波碎石术  胰管结石  镇痛
DOI:10.16781/j.0258-879x.2020.12.1346
投稿时间:2020-05-29修订日期:2020-07-21
基金项目:上海市优秀青年医学人才培养计划(2017YQ015),上海市青年科技启明星计划(19QA1408500).
Application of ultrasound-guided transversus abdominis plane block combined with target-controlled infusion of remifentanil in extracorporeal shock wave lithotripsy of pancreatic stones
WANG Chun1△,LU Jun1△,LI Bo1,CHEN Hui2,BO Lu-long1,BIAN Jin-jun1*
(1. Department of Anesthesiology, Changhai Hospital, Naval Medical University(Second Military Medical University), Shanghai 200433, China;
2. Department of Gastroenterology, Changhai Hospital, Naval Medical University(Second Military Medical University), Shanghai 200433, China
Co-first authors.
* Corresponding author)
Abstract:
Objective To evaluate the effect of ultrasound-guided transversus abdominis plane block (TAPB) combined with target-controlled infusion (TCI) of remifentanil in extracorporeal shock wave lithotripsy (ESWL) of pancreatic stones. Methods Sixty patients with pancreatic stones who received ESWL for the first time were randomly divided into R group and TR group (30 cases in each group). Patients in R group received TCI of remifentanil only, while patients in TR group received ultrasound-guided TAPB 30 min before TCI of remifentanil. Dixon's up-and-down method was used to calculate the half maximum effective concentration (EC50) of remifentanil. Perioperativevisual analog scale (VAS), Ramsay sedation scale, hemodynamic parameters, respiratory parameters, and adverse events were also recorded. Results The EC50 of remifentanil were 3.448 ng/mL (95% confidence interval[CI] 1.636-3.946 ng/mL) and 2.523 ng/mL (95% CI 0.744-2.991 ng/mL) in the R group and the TR group, respectively (P<0.05). The VAS score and the Ramsay sedation scale were comparable between the two groups (both P>0.05), and there were no significant differences in hemodynamics and respiratory parameters between the two groups (both P>0.05). Compared with the R group, the total incidence rate of adverse events was lower in the TR group (10.0%[3/30]vs 56.7%[17/30], P<0.001), and so was the incidence rate of itching (6.7%[2/30]vs 26.7%[8/30], P=0.038). Conclusion TAPB combined with TCI of remifentanil can provide satisfactory analgesia and sedation for ESWL of pancreatic stones, and can reduce the dosage of remifentanil, with less adverse events.
Key words:  ultrasound-guided  transversus abdominis plane block  targeted-controlled infusion  remifentanil  extracorporeal shock wave lithotripsy  pancreatic stone  analgesia